Methods of inhibiting pcsk9
AssigneesTrustees of Dartmouth College, Oregon Health & Science University
InventorsJimmy Wu, Sergio Fazio, Hagai Tavori
Life of this patent
Estimating the term…
Abstract
Provided herein are methods for inhibiting PCSK9, reducing PCSK9 levels, and for treating or preventing related conditions and disorders, in a subject, which includes administering to a subject an effective amount of a compound which includes derivatized cycloalkyl[b]indoles, e.g., cyclopenta-, cyclohexa- and cyclohepta[b]indoles.
Claims29
A method for reducing the PCSK9 level in a subject, the method comprising administering to the subject an effective amount of a compound of Formula I, or a pharmaceutically acceptable stereoisomer, isotope, solvate or salt thereof:
- wherein
- dashed bonds, independently, are present or absent;
- X is O, S, CR2 or NR1;
- Y is, for each occurrence, independently N or C(R6);
- Z1 is CH2, CH(R5), C(R5)2 or is absent;
- Z2 is CH2, CH(R5), C(R5)2, NR2 or is absent;
- Ra and Rb are absent, or independently selected from hydrogen, alkyl, hydroxyl, and amino;
- wherein Ra and Rb may combine to form a 5- or 6-membered ring;
- R1 is hydrogen, alkyl, alkenyl, alkynyl or aryl;
- R2 is, for each occurrence, independently selected from the group consisting of hydrogen, halogen, haloalkyl, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, —R7-cycloalkyl, aryl, —NHR7, Het, —NHHet, —NHR7Het, —OR8, —O-aryl, —OHet, —R7OR8, —NR8R9, —NR8-aryl, —R7NR8R9, —R7NR8-aryl, —R7C(O)R8, —C(O)R8, —CO2R8, —R7CO2R8, —C(O)NR8R9, —C(O)aryl, —C(O)NR8aryl, —C(O)Het, —C(O)NHR7Het, —R7C(O)NR8R9, —C(S)NR8R9, —R7C(S)NR8R9, —R7(NH)NR8R9, —C(NH)NR8R9, —R7C(NH)NR8R9, —S(O)2NR8R9, —S(O)2NR8aryl, —R7SO2NHCOR8, —R7SO2NR8R9, —R7SO2R8, —S(O)mR8, cyano, nitro, and azido;
- R3 is selected from the group consisting of hydrogen, halogen, haloalkyl, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, Het, aryl, —NHR7, —NHHet, —NHR7Het, —OR8, —O-aryl, —OHet, —R7OR8, —NR8R9, —NR8-aryl, —R7NR8R9, —R7NR8-aryl, —R7C(O)R8, —C(O)R8, —CO2R8, —R7CO2R8, —C(O)NR8R9, —C(O)aryl, —C(O)NR8aryl, —C(O)Het, —C(O)NHR7Het, —R7C(O)NR8R9, —C(S)NR8R9, —R7C(S)NR8R9, —R7(NH)NR8R9, —C(NH)NR8R9, —R7C(NH)NR8R9, —S(O)2NR8R9, —S(O)2NR8aryl, —R7SO2NHCOR8, —R7SO2NR8R9, —R7SO2R8, —S(O)mR8, cyano, nitro, and azido;
- R4 is selected from the group consisting of hydrogen, halogen, haloalkyl, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, Het, aryl, —NHR7, —NHHet, —NHR7Het, —OR8, —O-aryl, —OHet, —R7OR8, —NR8R9, —NR8-aryl, —R7NR8R9, —R7NR8-aryl, —CO(O)R8, —C(O)R8, —CO2R8, —R7CO2R8, —C(O)NR8R9, —C(O)aryl, —C(O)NR8aryl, —C(O)Het, —C(O)NHR7Het, —R7C(O)NR8R9, —C(S)NR8R9, —R7C(S)NR8R9, —R7(NH)NR8R9, —C(NH)NR8R9, —R7C(NH)NR8R9, —S(O)2NR8R9, —S(O)2NR8aryl, —R7SO2NHCOR8, —R7SO2NR8R9, —R7SO2R8, —S(O)mR8, cyano, nitro, and azido;
- R5 is, for each occurrence, independently selected from the group consisting of halogen, haloalkyl, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, Het, aryl, —NHR7, —NHHet, —NHR7Het, oxo, —OR8, —O-aryl, —OHet, —R7OR8, —NR8R9, —NR8-aryl, —R7NR8R9, —R7R8-aryl, —R7C(O)R8, —C(O)R8, —CO2R8, —R7CO2R8, —C(O)NR8R9, —C(O)aryl, —C(O)NR8aryl, —C(O)Het, —C(O)NHR7Het, —R7C(O)NR8R9, —C(S)NR8R9, —R7C(S)NR8R9, —R7(NH)NR8R9, —C(NH)NR8R9, —R7C(NH)NR8R9, —S(O)2NR8R9, —S(O)2NR8aryl, —R7SO2NHCOR8, —R7SO2NR8R9, —R7SO2R8, —S(O)mR7R8, cyano, nitro, and azido;
- R6 is, for each occurrence, independently selected from hydrogen, halogen, haloalkyl, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, —R7-cycloalkyl, aryl, —NHR7, Het, —NHHet, —NHR7Het, —OR8, —O-aryl, —OHet, —R7OR8, —NR8R9, —NR8-aryl, —R7NR8R9, —R7NR8-aryl, —R7C(O)R8, —C(O)R8, —CO2R8, —R7CO2R8, —C(O)NR8R9, —C(O)aryl, —C(O)NR8aryl, —C(O)Het, —C(O)NHR7Het, —R7C(O)NR8R9, —C(S)NR8R9, —R7C(S)NR8R9, —R7(NH)NR8R9, —C(NH)NR8R9, —R7C(NH)NR8R9, —S(O)2NR8R9, —S(O)2NR8, —R7SO2NHCOR8, —R7SO2NR8R9, —R7SO2R8, —S(O)mR8, cyano, nitro, and azido;
- R7 is independently selected from an alkyl, cycloalkyl alkenyl, cycloalkenyl and alkynyl
- R8 is independently selected from the group of hydrogen, an alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, —R7cycloalkyl, —R7OH, —R7(OR7)w, and —R7NR10R11 group;
- R9 is independently selected from the group of hydrogen, an alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, —R7cycloalkyl, —R7OH, —R7(OR7)w, and —R7NR10R11 group;
- R13 and R11 are the same or different and are independently selected from the group of alkyl, cycloalkyl, alkenyl, cycloalkenyl, and alkynyl;
- m, for each occurrence, independently is 0, 1 or 2;
- n is 0, 1, 2, 3, 4, 5 or 6;
- w is an integer selected from 1-10;
- and
- wherein any two of R2, R3, R4 and R5, or two R5, may combine to form a 5- or 6-membered ring.
The method of any one of the preceding claims, wherein the levels of both the pro-protein and mature forms of PCSK9 are reduced.
The method of any one of the preceding claims, wherein the secretion of PCSK9 is inhibited.
The method of any one of the preceding claims, wherein the production of PCSK9 is inhibited.
The method of any one of the preceding claims, wherein the level of low density lipoprotein receptor (LDLR) in the subject is increased.
The method of any one of the preceding claims, wherein the amount of low density lipoprotein (LDL) in the cell is decreased.
A method of treating or preventing a condition associated with an elevated level of LDL, the method comprising administering to a subject in need of such treatment an effective amount of a compound of Formula I.
The method of any one of the preceding claims, wherein the compound of Formula I is administered orally.
Dependencies are inferred from the claim text.